Strontium‑89 Chloride Injectable Metastatic Bone Radiotherapy Market 2026: Market Leaders Powering Global Oncology Pain Relief

MARKET INSIGHTS

The global Strontium‑89 Chloride Injectable Metastatic Bone Radiotherapy Market was valued at USD 125 million in 2025. The market is projected to grow from USD 132 million in 2026 to USD 245 million by 2034, exhibiting a CAGR of 8.1% during the forecast period.

Strontium‑89 Chloride Injectable is a radiopharmaceutical agent administered intravenously for the palliation of bone pain in patients with metastatic bone cancer. As a calcium analog, it selectively localizes in areas of high bone turnover associated with metastatic lesions, delivering targeted beta radiation to alleviate severe pain while minimizing impact on surrounding healthy tissue. This therapy is particularly valuable for patients with osteoblastic metastases, commonly from prostate, breast, or lung cancers, offering an important non‑opioid option for pain management in advanced disease stages.

The market is experiencing steady growth driven by the rising global incidence of cancers that frequently metastasize to bone, along with increasing recognition of targeted radiotherapies in palliative care. Advancements in nuclear medicine infrastructure and greater availability of specialized treatment centers are supporting wider adoption. Furthermore, the growing emphasis on improving quality of life for patients with advanced metastatic disease contributes to demand, as healthcare providers seek effective solutions beyond traditional analgesics. Key manufacturers continue to maintain stable supply chains for this established therapy, with ongoing efforts to optimize production and distribution ensuring reliable access for oncology practices worldwide.

Strontium‑89 Chloride Injectable Metastatic Bone Radiotherapy Market – View in Detailed Research Report

Strontium‑89 Chloride Injectable Metastatic Bone Radiotherapy Market – View in Detailed Research Report

Top 10 Companies in the Strontium‑89 Chloride Injectable Metastatic Bone Radiotherapy Market 2026

1. Jubilant Radiopharma (India)

Headquarters: Ahmedabad, India
Key Offering: Metastron™ Strontium‑89 Chloride

Jubilant Radiopharma has secured regulatory approvals across major markets and operates a dedicated GMP‑certified production line that guarantees a steady supply. Its focus on cost‑effective manufacturing and robust logistics positions it as the de‑facto reference source for oncology practices worldwide.

Sustainability Initiatives: Investment in renewable energy for production facilities and pursuit of ISO 14001 environmental certification.

• Global supply network covering emerging economies
• Dedicated isotope production line
• ISO 14001 environmental certification
• Ongoing R&D into extended‑release formulations

2. Radiopharma Sciences Ltd (India)

Headquarters: Mumbai, India
Key Offering: Strontium‑89 Chloride

Radiopharma Sciences recently obtained marketing authorization in India and is scaling production to meet the rising demand in South‑East Asia. Its regional distribution hub in Chennai supports rapid deployment to oncology centers.

Sustainability Initiatives: Partnerships with local universities for research and training.

• Cost‑effective production strategy
• Regional distribution center in Chennai
• Collaboration with academic institutions
• Focus on patient‑centric clinical trials

3. Centre of Radiopharmaceuticals (Poland)

Headquarters: Warsaw, Poland
Key Offering: Strontium‑89 Chloride

The state‑funded Centre supplies the EU under a limited quota, emphasizing strict compliance with EU directives. Its digital batch‑traceability system enhances transparency for clinical partners.

Sustainability Initiatives: Adoption of digital traceability for batch tracking.

• EU regulatory compliance
• State‑funded production capacity
• Digital batch traceability
• Support for EU‑wide clinical trials

4. Eurorad (France)

Headquarters: Paris, France
Key Offering: Strontium‑89 Chloride

Eurorad leverages its logistics expertise to deliver tailored solutions to French oncology clinics, ensuring optimal cold‑chain integrity.

Sustainability Initiatives: Optimizing cold‑chain logistics to reduce carbon footprint.

• Tailored delivery solutions
• Cold‑chain optimization
• Partnerships with French hospitals
• Emphasis on safety and compliance

5. Jiangsu Huayi Pharmaceutical Co. (China)

Headquarters: Nanjing, China
Key Offering: Strontium‑89 Chloride

Pilot‑scale production is underway to meet the growing demand in mainland China, driven by an aging population and expanding oncology infrastructure.

Sustainability Initiatives: Investment in advanced reactor technologies.

• Pilot‑scale production facility
• Advanced reactor technology
• Focus on supply stability
• Alignment with national healthcare priorities

6. Bristol Myers Squibb (USA)

Headquarters: New York, USA
Key Offering: Strontium‑89 Chloride

BMS is exploring the integration of Strontium‑89 with its oncology pipeline to enhance multimodal treatment options.

Sustainability Initiatives: Sustainability initiatives in research funding.

• Oncology pipeline integration
• Clinical trial collaborations
• Research funding for radiopharmaceuticals
• Commitment to patient‑centric care

7. Pfizer (USA)

Headquarters: New York, USA
Key Offering: Strontium‑89 Chloride

Pfizer’s oncology division is evaluating Strontium‑89 as a potential addition to its bone‑pain management portfolio.

Sustainability Initiatives: Investment in green chemistry for radiopharmaceuticals.

• Portfolio expansion – bone‑pain management
• Green chemistry initiatives
• Partnerships with academic centers
• Focus on cost‑effectiveness

8. Roche (Switzerland)

Headquarters: Basel, Switzerland
Key Offering: Strontium‑89 Chloride

Roche’s precision‑medicine approach positions Strontium‑89 within personalized palliative care strategies.

Sustainability Initiatives: Sustainability reporting for clinical programs.

• Precision‑medicine alignment
• Clinical program sustainability reporting
• Patient‑centric trials
• Integration with targeted therapies

9. Novartis (Switzerland)

Headquarters: Basel, Switzerland
Key Offering: Strontium‑89 Chloride

Novartis is developing companion diagnostics to guide Strontium‑89 therapy selection.

Sustainability Initiatives: Carbon‑neutral research facilities.

• Companion diagnostic development
• Carbon‑neutral research facilities
• Clinical data integration
• Support for global clinical trials

10. Sanofi (France)

Headquarters: Paris, France
Key Offering: Strontium‑89 Chloride

Sanofi’s oncology arm is collaborating with national health agencies to expand access to Strontium‑89.

Sustainability Initiatives: Investment in equitable access programs.

• Collaboration with health agencies – access expansion
• Equitable access programs
• Clinical trial support – EU & global distribution
• Patient‑centric care initiatives

Download FREE Sample Report: Strontium‑89 Chloride Injectable Metastatic Bone Radiotherapy Market – View in Detailed Research Report
Get Full Report: Strontium‑89 Chloride Injectable Metastatic Bone Radiotherapy Market – View in Detailed Research Report

Outlook

As the population ages and cancer survival improves, the cohort of patients with bone metastases will expand, driving demand for effective pain‑management solutions. The market is expected to benefit from ongoing investments in nuclear medicine infrastructure, tighter reimbursement frameworks that reward value, and an increasing focus on multidisciplinary care pathways that incorporate Strontium‑89 alongside systemic therapies.

Future Trends

• Advanced imaging modalities will sharpen patient selection, increasing the precision of Strontium‑89 therapy.
• Nanoparticle‑enhanced formulations are poised to improve biodistribution and reduce off‑target effects.
• Combination strategies with immuno‑oncology agents may open new therapeutic indications.
• Regulatory harmonization across regions will lower entry barriers for new manufacturers.
• Cost‑effective, value‑based reimbursement models will shape adoption patterns.